September 13, 2026

Morgan Stanley Cuts Novo Nordisk to Underweight, HSBC Raises to DKK 320, Corbus CANYON-1 Monday Topline Countdown

Morgan Stanley cuts Novo Nordisk to Underweight on semaglutide patent cliff, HSBC lifts target to DKK 320, Corbus CANYON-1 Monday morning topline countdown.

4 stories · Covering industry, clinical-trials, research

Editor's Note

Sunday's news window ran quiet as the industry looked ahead to Monday's Corbus CANYON-1 Phase 1b topline readout for CRB-913 (a peripherally-restricted CB1 inverse agonist that would establish a non-incretin oral obesity option if the dose-response curve holds). The dominant week-ending narrative was a split analyst reaction to Novo Nordisk from Copenhagen: Morgan Stanley cut the stock to Underweight from Equal-weight Friday September 11 on concerns about the semaglutide patent-cliff exposure (Novo derives approximately 75% of 2026 sales from semaglutide with loss of exclusivity beginning 2031), taking the price target to DKK 250; HSBC on Wednesday September 9 had raised its target to DKK 320 from DKK 300 while maintaining Hold. Novo shares closed the week down about 2.8% in Copenhagen and 3.1% in Frankfurt. Amgen weekend commentary continued the theme that MariTide (maridebart cafraglutide, antibody-peptide conjugate) stands alone as the company's sole obesity asset after the August 4 discontinuation of AMG 513, with executives at last week's Wells Fargo conference positioning MariTide as the potential best monthly or quarterly obesity option. And a running Medscape systematic review-and-meta-analysis synthesized 10 head-to-head studies (three RCTs, seven retrospective cohorts) across 41,381 adults, finding tirzepatide produced ~4.3 percentage points more weight loss than semaglutide with a comparable gastrointestinal safety profile but somewhat higher serious adverse event rates. Sunday news volume was thin; verification took priority over quotas.

Industry

Morgan Stanley Downgrades Novo Nordisk to Underweight Friday, Target Cut to DKK 250 on Semaglutide Patent Cliff Exposure; HSBC's Wednesday Move to DKK 320 Hold Frames the Analyst Split

Morgan Stanley analyst Thibault Boutherin and team cut Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) to Underweight from Equal-weight on Friday September 11, 2026, with a DKK 250 price target implying more than 10% downside from current levels. The downgrade thesis: Novo's current valuation does not fully reflect the subdued mid-term growth outlook or the semaglutide patent-cliff implications on the company's terminal value. Semaglutide is expected to account for approximately 75% of Novo's 2026 sales; loss of exclusivity begins in 2031 across major markets. Morgan Stanley also flagged weaker momentum in U.S. Wegovy pill prescriptions following a stronger first half of 2026. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. HSBC on Wednesday September 9 had raised its price target to DKK 320 (from DKK 300) while maintaining a Hold rating, framing the analyst split. Barclays cut its price target to DKK 300 from DKK 310 September 8 following the STEP Young + ziltivekimab HERMES/ATHENA split announcement, and Guggenheim earlier moved its target on Roivant/Pulmovant PHocus success. Novo executed DKK 9.02 billion of the DKK 15 billion share repurchase through September 4.

#novo-nordisk #nvo #novo-b #morgan-stanley #underweight-downgrade #dkk-250-price-target #semaglutide-patent-cliff #hsbc-dkk-320-hold #barclays-dkk-300 #boutherin-thibault #2031-loss-of-exclusivity #75-percent-semaglutide-concentration #share-repurchase-programme #glp-1

Clinical Trials

Corbus CANYON-1 Phase 1b Topline Data on CRB-913 Peripherally-Restricted CB1 Inverse Agonist Landing Monday September 14 at 8 a.m. EDT; Weekend Positioning for Non-Incretin Obesity Landscape

Corbus Pharmaceuticals (NASDAQ: CRBP) enters Sunday September 13, 2026 the final day of the countdown to Monday September 14 at 8:00 a.m. EDT conference call disclosing Phase 1b CANYON-1 topline data for CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults across once-daily doses of 20 mg, 40 mg, and 60 mg (titrated from 20 mg over four weeks) with a 4-week safety follow-up (NCT07310901). Harold Bays MD (investigator) joins Corbus management. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off: peripheral restriction (approximately 15-fold lower brain penetration than monlunabant in preclinical models) is designed to preserve dose-responsive weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). Corbus previously reported Phase 1a mean 2.9% placebo-adjusted weight loss by Day 14. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as one of the earliest non-incretin oral obesity options alongside Novo Nordisk cagrilintide (amylin), Structure Therapeutics aleniglipron (oral small-molecule GLP-1), and the Roche petrelintide-enicepatide combo Phase 2.

#corbus-pharmaceuticals #crbp #crb-913 #canyon-1-monday #topline-september-14 #8-am-edt-conference-call #harold-bays-investigator #peripherally-restricted-cb1-inverse-agonist #240-participants #monlunabant-comparator #rimonabant-history #non-incretin-obesity #phase-1a-2-9-percent-day-14 #obesity #non-peptide

Research

Tirzepatide vs Semaglutide Head-to-Head Systematic Review Across 10 Studies (Three RCTs, Seven Retrospective Cohorts) and 41,381 Adults Confirms 4.3 Percentage Points Greater Weight Loss With Tirzepatide Alongside Higher Serious Adverse Event Rate

A systematic review and meta-analysis of head-to-head comparisons of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy) in adults with overweight or obesity — published in Diabetes, Obesity and Metabolism and covered by Medscape on September 9, 2026 with running weekend commentary — synthesized 10 studies (three randomized controlled trials and seven retrospective cohort studies) enrolling 41,381 adults. Tirzepatide produced a mean 4.28 percentage-point greater percent-body-weight reduction than semaglutide (10 studies) and a mean 4.43 kg greater absolute weight loss (8 studies). One head-to-head study reported average weight loss of 50.3 lbs (22.9 kg) on tirzepatide versus 33.1 lbs on semaglutide. Gastrointestinal adverse events were common in both arms but somewhat more frequent with tirzepatide; serious adverse event rates were rare but higher on tirzepatide than semaglutide. The pooled evidence supports the SURMOUNT-5 head-to-head randomized readout published in the New England Journal of Medicine in 2025 (Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks). The tirzepatide-semaglutide efficacy gap plus the safety trade-off remains a live clinical decision point in a market where 12%+ of U.S. adults are on the GLP-1 class per recent surveys.

#tirzepatide #semaglutide #head-to-head-meta-analysis #diabetes-obesity-metabolism #10-studies #41381-adults #3-rcts-7-cohorts #4-28-percent-greater-weight-loss #4-43-kg-absolute #serious-adverse-events-higher-tirzepatide #surmount-5-context #medscape-coverage #peptide-clinical-decisions #glp-1

Industry

Amgen MariTide Stands Alone as Sole Obesity Asset After AMG 513 August Discontinuation; Wells Fargo Week Extended-Dosing Positioning Continues Into Weekend Commentary

Amgen (NASDAQ: AMGN) executive commentary continued through the weekend of September 12-13, 2026 following Thursday's Wells Fargo Healthcare Conference in Boston, reinforcing that MariTide (maridebart cafraglutide, antibody-peptide conjugate combining a GLP-1 receptor agonist peptide with a GIP receptor antagonist antibody scaffold) is Amgen's sole obesity asset following the August 4, 2026 Q2 earnings-call disclosure that Amgen had discontinued Phase 1 candidate AMG 513. The AMG 513 discontinuation followed a similar Amgen fate for AMG 786 in 2024 and reflects the company's high internal efficacy bar for obesity assets against the emerging retatrutide (Lilly, ~28% weight loss in TRIUMPH-1) and CagriSema (Novo, ~20% in REDEFINE) benchmarks. Amgen's positioning for MariTide anchors on 8-week or quarterly maintenance dosing (4-6 doses per year), Phase 2 20% weight loss at 52 weeks, and cardiometabolic secondary benefits (triglycerides, hs-CRP, blood pressure). MARITIME-SWITCH Phase 3 tests conversion from weekly injectable semaglutide or tirzepatide to monthly MariTide. Analysts continue to seek Amgen M&A activity to broaden the obesity asset base, but company executives at Wells Fargo said the late-stage pipeline is largely full and business development will focus on earlier-stage opportunities.

#amgen #amgn #maritide #maridebart-cafraglutide #antibody-peptide-conjugate #amg-513-discontinued #amg-786-discontinuation-context #sole-obesity-asset #8-week-quarterly-dosing #maritime-switch-phase-3 #retatrutide-benchmark #cagrisema-benchmark #wells-fargo-follow-through #analyst-m-a-pressure